Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Boston Scientific Corp (BSX)

Boston Scientific Corp (BSX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Is Boston Scientific Stock Underperforming the Dow?

The Marlborough, Massachusetts-based Boston Scientific Corporation (BSX) designs and commercializes medical devices that power minimally invasive procedures across cardiovascular, urology, neurology, oncology, and gastrointestinal care. 

With a market capitalization of about $111.5 billion, the company stands in the “large-cap” territory, a bracket reserved for businesses valued above $10 billion. This scale provides reach, capital flexibility, and a global sales infrastructure that supports hospitals and specialists across developed and emerging markets alike. 

Fundamentals

See More
  • Market Capitalization, $K 109,035,880
  • Shares Outstanding, K 1,483,885
  • Annual Sales, $ 20,074 M
  • Annual Income, $ 2,898 M
  • EBIT $ 4,509 M
  • EBITDA $ 5,923 M
  • 60-Month Beta 0.67
  • Price/Sales 5.56
  • Price/Cash Flow 18.62
  • Price/Book 4.56

Options Overview Details

View History
  • Implied Volatility 31.66% (+0.96%)
  • Historical Volatility 61.24%
  • IV Percentile 83%
  • IV Rank 40.44%
  • IV High 52.68% on 04/04/25
  • IV Low 17.38% on 07/29/25
  • Expected Move (DTE 7) 1.99 (2.63%)
  • Put/Call Vol Ratio 1.39
  • Today's Volume 24,393
  • Volume Avg (30-Day) 30,481
  • Put/Call OI Ratio 0.46
  • Today's Open Interest 372,705
  • Open Int (30-Day) 418,371
  • Expected Range 73.76 to 77.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.79
  • Number of Estimates 9
  • High Estimate 0.80
  • Low Estimate 0.78
  • Prior Year 0.75
  • Growth Rate Est. (year over year) +5.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
72.69 +4.21%
on 02/11/26
94.46 -19.81%
on 01/28/26
-17.80 (-19.03%)
since 01/26/26
3-Month
72.69 +4.21%
on 02/11/26
101.91 -25.67%
on 12/01/25
-25.21 (-24.97%)
since 11/26/25
52-Week
72.69 +4.21%
on 02/11/26
109.50 -30.82%
on 09/09/25
-25.81 (-25.41%)
since 02/26/25

Most Recent Stories

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX

NEW YORK , Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX). Such...

BSX : 75.75 (+3.09%)
Is Boston Scientific Stock Underperforming the Dow?

Boston Scientific’s shares are trailing the broader market, yet analysts remain optimistic, signaling confidence in longer-term recovery potential.

ABT : 116.26 (+1.31%)
BSX : 75.75 (+3.09%)
$DOWI : 49,499.20 (+0.03%)
Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

ALAMEDA, Calif. , Feb. 25, 2026 /PRNewswire/ -- Penumbra, Inc. ( NYSE: PEN ) , the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year...

BSX : 75.75 (+3.09%)
PEN : 341.94 (+0.97%)
Q4 Earnings Highlights: Boston Scientific (NYSE:BSX) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks

Q4 Earnings Highlights: Boston Scientific (NYSE:BSX) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks

BSX : 75.75 (+3.09%)
Is Abbott Laboratories Stock Underperforming the Nasdaq?

Abbott Laboratories has underperformed the Nasdaq over the past year, but analysts are highly optimistic about the stock’s prospects.

ABT : 116.26 (+1.31%)
$NASX : 22,878.38 (-1.18%)
BSX : 75.75 (+3.09%)
Ongoing Investigation into Boston Scientific Corporation (BSX): Contact Levi & Korsinsky About Potential Fraud

New York, New York--(Newsfile Corp. - February 23, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Boston Scientific Corporation ("Boston Scientific Corporation")...

BSX : 75.75 (+3.09%)
Boston Scientific elects Cathy Smith and Christophe Weber to Board of Directors

MARLBOROUGH, Mass. , Feb. 23, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today the election of Cathy Smith and Christophe Weber to its Board of Directors, effective...

BSX : 75.75 (+3.09%)
Ongoing Investigation: Boston Scientific Corporation (BSX) May Have Misled Shareholders - Levi & Korsinsky Investigates

New York, New York--(Newsfile Corp. - February 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Boston Scientific Corporation ("Boston Scientific Corporation")...

BSX : 75.75 (+3.09%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX

NEW YORK , Feb. 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX). Such...

BSX : 75.75 (+3.09%)
3 S&P 500 Stocks Worth Investigating

3 S&P 500 Stocks Worth Investigating

TT : 457.14 (-0.63%)
BSX : 75.75 (+3.09%)
ZTS : 129.76 (+0.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 30%. The market has bounced from oversold territory. Beware of a potential mean reversion.

See More Share

Business Summary

Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and...

See More

Key Turning Points

3rd Resistance Point 78.74
2nd Resistance Point 77.30
1st Resistance Point 76.53
Last Price 75.75
1st Support Level 74.32
2nd Support Level 72.88
3rd Support Level 72.11

See More

52-Week High 109.50
Fibonacci 61.8% 95.44
Fibonacci 50% 91.10
Fibonacci 38.2% 86.75
Last Price 75.75
52-Week Low 72.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar